News | 29 September 2025
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
BIL also holds an option to increase its equity stake by an additional 15%
The CSR initiative will offer Digital Radiology X-Ray service to Dholera and 33 surrounding villages in the region
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
The expansion, supported by a significant UK government grant, includes a new lipid system synthesis facility and enhanced R&D capabilities
Ultra-high purity surfactant for biologics and parenteral drug formulations
Relonchem receives marketing authorization for Moxonidine tablets
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Prolia is a prescription medicine used to treat osteoporosis in women
Corning and SGD Pharma formed JV in June 2023 to expand pharmaceutical manufacturing in India
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Agency initiates safety label change and notifies physicians of possible link
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Subscribe To Our Newsletter & Stay Updated
